Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis
- PMID: 9728571
- DOI: 10.1086/515354
Therapeutic effect of interferon-gamma gene transfer in experimental visceral leishmaniasis
Abstract
Interferon (IFN)-gamma, in both natural endogenous form and administered as exogenous protein, induces control over visceral Leishmania donovani in experimentally infected BALB/c mice. To further characterize the therapeutic role of IFN-gamma in host defense against intracellular L. donovani, the efficacy of IFN-gamma delivered by gene transfer was tested. One week after infection, normal and IFN-gamma gene-disrupted (GKO) BALB/c mice were injected with an IFN-gamma gene-bearing mammalian expression plasmid (pIFN). Plasmid-specific IFN-gamma transcripts were detected in liver and spleen. Whereas liver parasite burdens more than doubled in untreated and mock-treated normal and GKO mice during the subsequent 2 weeks, animals injected with pIFN had controlled visceral infection and reduced parasite burden. These results indicate that, in infected tissues, IFN-gamma delivered by gene transfer enhances control over disseminated intracellular infection.
Similar articles
-
Effect of continuous administration of interferon-gamma in experimental visceral leishmaniasis.J Infect Dis. 1990 May;161(5):992-4. doi: 10.1093/infdis/161.5.992. J Infect Dis. 1990. PMID: 2157773
-
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma.J Immunol. 1987 Apr 1;138(7):2290-7. J Immunol. 1987. PMID: 3104456
-
The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice.J Interferon Cytokine Res. 2000 Jan;20(1):63-77. doi: 10.1089/107999000312748. J Interferon Cytokine Res. 2000. PMID: 10670653
-
The role of interferon-gamma in the treatment of visceral and diffuse cutaneous leishmaniasis.J Infect Dis. 1993 Mar;167 Suppl 1:S13-7. doi: 10.1093/infdis/167.supplement_1.s13. J Infect Dis. 1993. PMID: 8433014 Review.
-
Current and future clinical applications of interferon-gamma in host antimicrobial defense.Intensive Care Med. 1996 Oct;22 Suppl 4:S456-61. doi: 10.1007/BF01743724. Intensive Care Med. 1996. PMID: 8923089 Review.
Cited by
-
Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis.Infect Immun. 2005 Oct;73(10):6372-82. doi: 10.1128/IAI.73.10.6372-6382.2005. Infect Immun. 2005. PMID: 16177308 Free PMC article.
-
Generation of ceramide in murine macrophages infected with Leishmania donovani alters macrophage signaling events and aids intracellular parasitic survival.Mol Cell Biochem. 2001 Jul;223(1-2):47-60. doi: 10.1023/a:1017996609928. Mol Cell Biochem. 2001. PMID: 11681721
-
Clinical and experimental advances in treatment of visceral leishmaniasis.Antimicrob Agents Chemother. 2001 Aug;45(8):2185-97. doi: 10.1128/AAC.45.8.2185-2197.2001. Antimicrob Agents Chemother. 2001. PMID: 11451673 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical